Patients with elevated levels of IL-4 and IL-17 have a high risk of developing DCM in patients with VMC; on the addition of IL-4 and IL-17 to the standard model (age, sex, and LVEF), the predictive power of progression to DCM is improved. This evidence concerns the gene IL17A and familial dilated cardiomyopathy.